Trials / Completed
CompletedNCT01165983
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | 0mg tablet, taken orally for 12 weeks daily |
| DRUG | Aliskiren | 150mg tablet, taken orally for 12 weeks daily |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-01-01
- First posted
- 2010-07-20
- Last updated
- 2017-03-28
- Results posted
- 2015-02-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01165983. Inclusion in this directory is not an endorsement.